Elke De Bruyne

Brussels, BRU, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 100 publications

Clinical applications of epigenetic signatures in chronic pain management and health outcome prediction.

Clinical applications of epigenetic signatures in chronic pain management and health outcome prediction.

Journal: Epigenomics

Published: July 22, 2026

Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses.

Adrenergic stimulation of bone marrow immunity differentially affects myeloma growth and immunotherapy responses.

Journal: Cancer letters

Published: April 15, 2026

Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia.

Hypermethylation of OPRM1: Deregulation of the Endogenous Opioid Pathway in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia.

Journal: International journal of molecular sciences

Published: December 03, 2025

A Syndecan-Based Genetic Approach to Coat the Surface of Small Extracellular Vesicles With Nanobodies.

A Syndecan-Based Genetic Approach to Coat the Surface of Small Extracellular Vesicles With Nanobodies.

Journal: Journal of extracellular biology

Published: November 20, 2025

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.

IgG2a-formatted 4-1BB agonism combined with S100A9 inhibition enhances T cell activation and tumor control in a preclinical model of multiple myeloma.

Journal: Journal of experimental & clinical cancer research : CR

Published: November 18, 2025

T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.

T cell senescence and exhaustion: molecular mechanisms and immune rejuvenation for cancer immunotherapy.

Journal: Signal transduction and targeted therapy

Published: November 03, 2025

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.

Characterizing the Fate of Anti-CS1 Nanobody Displaying Extracellular Vesicles in Multiple Myeloma.

Journal: Journal of extracellular vesicles

Published: July 08, 2025

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Hypoxia promotes BCMA loss and a suppressive secretome thereby hindering CAR T cell therapy in multiple myeloma.

Journal: Experimental hematology & oncology

Published: July 04, 2025

The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism.

The clinically available supplement pyruvate enhances the therapeutic effect of bortezomib in Multiple Myeloma by modulating mitochondrial metabolism.

Journal: Cancer letters

Published: June 20, 2025

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escape.

Journal: Journal of hematology & oncology

Published: June 03, 2025

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.

Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy.

Journal: Journal for immunotherapy of cancer

Published: April 05, 2025

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation.

Combinatorial DNMTs and EZH2 inhibition reprograms the H3K27me3 and DNAme-mediated onco-epigenome to suppress multiple myeloma proliferation.

Journal: Scientific reports

Published: March 24, 2025

Showing 1-12 of 100

Last Updated: 09/26/2026